Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses

Journal: Nature Medicine

Published: 2018-07-23

DOI: 10.1038/s41591-018-0116-5

Affiliations: 19

Authors: 38

Go to article
Institutions FC
Department of Medical Oncology, DFCI, United States of America (USA) 0.42
Robert and Renée Belfer Center for Applied Cancer Science (The Belfer Center), DFCI, United States of America (USA) 0.08
Department of Pathology, BWH, United States of America (USA) 0.08
Department of Computer Science (CS), NJIT, United States of America (USA) 0.05
Department of Oncologic Pathology, DFCI, United States of America (USA) 0.05
Department of Gastroenterological Surgery, Kumamoto University, Japan 0.04
Cancer Institute, JFCR, Japan 0.04
Molecular and Cellular Oncogenesis Program, The Wistar Institute, United States of America (USA) 0.03
Department of Pediatric Oncology, DFCI, United States of America (USA) 0.03
Broad Institute of MIT and Harvard, United States of America (USA) 0.03
The Wistar Institute Melanoma Research Center, United States of America (USA) 0.03
Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University, Japan 0.03
Department of Surgery, BWH, United States of America (USA) 0.03
Cancer Center, MGH, United States of America (USA) 0.01
Moores Cancer Center, UC San Diego, United States of America (USA) 0.01
School of Medicine (SOM), UC San Diego, United States of America (USA) 0.01
NYU Laura and Isaac Perlmutter Cancer Center, United States of America (USA) 0.01
Division of Pulmonary, Critical Care and Sleep Medicine, ISMMS, United States of America (USA) 0.01
Tisch Cancer Institute (TCI), ISMMS, United States of America (USA) 0.01

Return